Europos Sąjunga - graikų - EMA (European Medicines Agency)

dynavax gmbh - επιφανειακό αντιγόνο ηπατίτιδας Β - Ηπατίτιδα Β - Εμβόλια - heplisav b is indicated for the active immunisation against hepatitis b virus infection (hbv) caused by all known subtypes of hepatitis b virus in adults 18 years of age and older. the use of heplisav b should be in accordance with official recommendations. it can be expected that hepatitis d will also be prevented by immunisation with heplisav b as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection.